LEADER 00842nam0-22003011i-450-
001 990000475040403321
005 20101108161334.0
010   $a0-674-32659-8
035   $a000047504
035   $aFED01000047504
035   $a(Aleph)000047504FED01
035   $a000047504
100   $a20020821d1976----km-y0itay50------ba
101 0 $aeng
105   $aa-------001yy
200 1 $aFrontiers of astrophysics$fEugene H. Avrett
210   $aCambridge, Massachusetts$cHarvard University press$d1976
215   $a554 p.$cill.$d23 cm
610 0 $aAstrofisica
676   $a523.01
700  1$aAvrett,$bEugene H.$f<1933- >$026093
801  0$aIT$bUNINA$gRICA$2UNIMARC
901   $aBK
912   $a990000475040403321
952   $a10 B I 254$b10137$fDINEL
959   $aDINEL
996   $aFrontiers of astrophysics$9332170
997   $aUNINA

LEADER 01541nam  2200421Ia 450 
001 9910698978503321
005 20090618110942.0
035   $a(CKB)5470000002398088
035   $a(OCoLC)402487747
035   $a(EXLCZ)995470000002398088
100   $a20090618d2005      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $eS7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT Interval Prolongation) by human pharmaceuticals
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research :$cCenter for Biologics Evaluation and Research,$d[2005]
215   $a10 pages $cdigital, PDF file
300   $aTitle from PDF title page (viewed on June 19th, 2009).
300   $a"ICH".
300   $a"October 2005".
517   $aGuidance for industry 
606   $aHeart$xVentricles
606   $aPalpitation
606   $aDrugs$xTesting
615  0$aHeart$xVentricles.
615  0$aPalpitation.
615  0$aDrugs$xTesting.
712 02$aCenter for Drug Evaluation and Research (U.S.)
712 02$aCenter for Biologics Evaluation and Research (U.S.)
712 12$aInternational Conference on Harmonisation.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910698978503321
996   $aGuidance for industry$93434577
997   $aUNINA